Thrive Wealth Management LLC Takes $210,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Thrive Wealth Management LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,000 shares of the medical research company’s stock, valued at approximately $210,000.

Several other large investors also recently added to or reduced their stakes in CRL. Private Advisor Group LLC raised its holdings in Charles River Laboratories International by 15.4% in the 1st quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after purchasing an additional 178 shares during the period. Panagora Asset Management Inc. raised its stake in shares of Charles River Laboratories International by 236.5% in the first quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock worth $773,000 after buying an additional 1,913 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Charles River Laboratories International by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock valued at $1,917,000 after buying an additional 418 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in Charles River Laboratories International by 0.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock worth $7,465,000 after acquiring an additional 107 shares in the last quarter. Finally, Raymond James Trust N.A. increased its holdings in Charles River Laboratories International by 33.7% in the 1st quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after acquiring an additional 384 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Up 1.3 %

CRL stock opened at $210.62 on Tuesday. The firm has a fifty day moving average price of $206.21 and a 200 day moving average price of $202.53. Charles River Laboratories International, Inc. has a fifty-two week low of $181.22 and a fifty-two week high of $262.00. The firm has a market cap of $10.80 billion, a PE ratio of 22.34, a price-to-earnings-growth ratio of 1.86 and a beta of 1.33. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.21 and a current ratio of 1.49.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm posted $2.77 EPS. The business’s quarterly revenue was up 8.9% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Monday. Citigroup lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the stock from $260.00 to $225.00 in a research note on Monday, July 10th. Bank of America boosted their price objective on Charles River Laboratories International from $235.00 to $245.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. TD Cowen initiated coverage on Charles River Laboratories International in a research report on Wednesday, September 13th. They set a “market perform” rating and a $212.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $244.55.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 700 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $216.52, for a total value of $151,564.00. Following the completion of the transaction, the executive vice president now owns 24,983 shares in the company, valued at approximately $5,409,319.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Richard F. Wallman bought 1,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 24th. The shares were acquired at an average price of $198.79 per share, with a total value of $198,790.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $198,790. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 700 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $216.52, for a total transaction of $151,564.00. Following the transaction, the executive vice president now directly owns 24,983 shares of the company’s stock, valued at $5,409,319.16. The disclosure for this sale can be found here. Insiders have sold a total of 7,934 shares of company stock worth $1,722,048 over the last ninety days. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).